Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i editorial
19 July 2016

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
SPPARM?: a concept becomes clinical realityRead more...

Peroxisome proliferator-activated receptor alpha (PPAR?) agonists – fibrates – are perhaps the best option among available agents for managing atherogenic dyslipidaemia, a key contributor to lipid-related residual cardiovascular risk.
However, this benefit is not without downsides, notably the potential for elevation in serum creatinine and liver enzymes, as well as precautions for their use in renal disease.
To counter these effects, it has been proposed that modifying the receptor–cofactor binding profile of the PPAR ligand may result in improved potency and tissue selectivity, and at the same time limit potentially deleterious adverse effects...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
19 July 2016

Analysis questions benefit of lowering LDL-C below current targetsRead more...

Despite attainment of guideline-recommended LDL-C targets with statin therapy, individuals with cardiovascular disease continue to be at risk of (recurrent) events. To reduce this risk, it has been proposed that LDL-C levels should be lowered below these targets. This approach is supported by evidence from...
focus on...
19 July 2016

K-877, a novel SPPARM? agent, for reducing atherogenic lipoproteins: Phase II results Read more...

This phase II study shows promising results with the first SPPARMα agent in patients with atherogenic dyslipidaemia (elevated TG and low HDL-C). The study showed a dose-dependent effect for TG lowering, with an apparent plateau at 0.1 mg twice daily, with superior reduction at the...
recent publication

ACCORDION: Benefit of fenofibrate on diabetic retinopathy did not persist long-termRead more...

The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye...
recent publication

HDL cholesterol paradox in residual cardiovascular riskRead more...

Data from the prospective Second Manifestations of ARTerial disease (SMART)...
recent publication

Positive data with apolipoproteinCIII antisense agentRead more...

In type 2 diabetes patients, the apolipoprotein(apo) CIII antisense agent...
recent publication

Fitness and atherogenic dyslipidaemiaRead more...

Maintaining fitness over the long-term protects against the development of...
recent publication

AIM-HIGH: should we refocus on HDL subfractions?Read more...

AIM-HIGH failed to show that targeting high-density lipoprotein cholesterol (HDL-C)...
recent publication

Lipid-lowering for primary cardiovascular prevention in type 1 diabetesRead more...

Findings from the Swedish National Diabetes Register show the importance...

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.